Analysts Set Expectations for BPMC FY2027 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Zacks Research issued their FY2027 earnings estimates for Blueprint Medicines in a research report issued to clients and investors on Wednesday, March 5th. Zacks Research analyst A. Chakraborty expects that the biotechnology company will earn $3.20 per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share.

Other research analysts also recently issued research reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Wedbush reaffirmed an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research report on Friday, February 28th. JPMorgan Chase & Co. raised their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. StockNews.com cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Needham & Company LLC restated a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.83.

Blueprint Medicines Trading Down 1.5 %

NASDAQ:BPMC opened at $88.54 on Thursday. The company’s 50 day moving average is $99.49 and its 200-day moving average is $94.31. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines has a 12 month low of $80.68 and a 12 month high of $121.90. The firm has a market cap of $5.66 billion, a price-to-earnings ratio of -81.98 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC bought a new position in shares of Blueprint Medicines during the 4th quarter valued at about $103,356,000. Wellington Management Group LLP raised its holdings in shares of Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after acquiring an additional 729,055 shares during the period. Norges Bank bought a new stake in Blueprint Medicines in the 4th quarter valued at $62,028,000. State Street Corp boosted its stake in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after purchasing an additional 385,818 shares during the period. Finally, Jennison Associates LLC bought a new position in Blueprint Medicines during the 4th quarter worth about $31,417,000.

Insider Buying and Selling

In other news, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,427 shares of company stock valued at $4,837,801 over the last ninety days. Insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.